Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
- Resource Type
- article
- Authors
- Adi Kartolo; Cynthia Yeung; Markus Kuksis; Wilma Hopman; Tara Baetz
- Source
- Melanoma Management, Vol 9, Iss 1 (2022)
- Subject
- BRAF V600 negative
immune checkpoint inhibitor
immunotherapy
melanoma
metastatic
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
- Language
- English
- ISSN
- 2045-0893
2045-0885
Aim: To evaluate the efficacy of dual versus single immune checkpoint inhibitors (ICI) in BRAF wild-type advanced melanoma patients. Materials & methods: A retrospective study of all advanced BRAF wild-type melanoma patients on palliative-intent ICI between 2015 and 2020 (n = 67). Results: Dual ICI had better overall survival (OS) when compared with single ICI in BRAF wild-type patients (hazard ratio: 0.204; 95% CI: 0.064–0.649; p = 0.007), but lost its statistical significance (median OSl not reached vs 20.9 months; p = 0.213; adjusted hazard ratio: 0.475; 95% CI: 0.164–1.380; p = 0.171) when only including patients treated after 2018 when dual ICI was funded in our province. Dual ICI were significantly associated with more frequent (p = 0.005) and severe (p = 0.026) immune-related adverse events, and required more immune-related adverse events-indicated systemic corticosteroid use (p